Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

Fingolimod has shown reductions in clinical and MRI disease activity in patients with relapsing-remitting multiple sclerosis. We further assessed the efficacy and safety of fingolimod in such patients. We did this placebo-controlled, double-blind phase 3 study predominantly in the USA (101 of 117 ce...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lancet neurology Jg. 13; H. 6; S. 545 - 556
Hauptverfasser:	Calabresi, Peter A, Radue, Ernst-Wilhelm, Goodin, Douglas, Jeffery, Douglas, Rammohan, Kottil W, Reder, Anthony T, Vollmer, Timothy, Agius, Mark A, Kappos, Ludwig, Stites, Tracy, Li, Bingbing, Cappiello, Linda, von Rosenstiel, Philipp, Lublin, Fred D
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England Elsevier Ltd 01.06.2014 Elsevier Limited
Schlagworte:	Adolescent Adult Disability Evaluation Disease Progression Double-Blind Method Drug Administration Schedule Drug dosages Drug therapy Female Fingolimod Hydrochloride Humans Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - adverse effects Immunosuppressive Agents - pharmacology Infections Magnetic Resonance Imaging Male Middle Aged Multiple sclerosis Multiple Sclerosis, Relapsing-Remitting - drug therapy Neurology Patients Placebos Propylene Glycols - administration & dosage Propylene Glycols - adverse effects Propylene Glycols - pharmacology Regulatory approval Secondary Prevention Sphingosine - administration & dosage Sphingosine - adverse effects Sphingosine - analogs & derivatives Sphingosine - pharmacology Studies Treatment Outcome Young Adult
ISSN:	1474-4422, 1474-4465, 1474-4465
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!